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Review
Objectives: We carried out a bibliometric study on the 
scientific publications in relation to atypical antipsychotic 
drugs (AADs) in Spain.
Methods: We used the EMBASE and MEDLINE databases 
and we applied some bibliometric indicators of paper 
production and dispersion (Price’s law and Bradford’s law, 
respectively). We also calculated the participation index of the 
different countries and correlated the bibliometric data with 
some social and health data (total per capita expenditure on 
health and gross domestic expenditure on research and 
development).
Results: We collected 656 original papers published 
between 1988 and 2011. Our study results fulfilled Price’s law 
with scientific production on AADs showing exponential 
growth (correlation coefficient r = 0.9693, vs. r = 0.9177 after 
linear adjustment). The most widely studied drugs were 
risperidone (181 papers), olanzapine (143), clozapine (94), 
and quetiapine (74). Division into Bradford zones yielded a 
nucleus occupied by the European Psychiatry and European 
Neuropsychopharmacology (70 articles). Totally 194 
different journals were published, with 5 of the first 10 used 
journals having an impact factor being greater than 4.
Conclusion: The publications on AADs in Spain have 
undergone exponential growth over the studied period, 
without evidence of reaching a saturation point. 
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La investigación sobre fármacos antipsicóticos 
atípicos en España: una evaluación bibliométrica
Objetivos: Se llevó a cabo un estudio bibliométrico de las 
publicaciones sobre fármacos antipsicóticos atípicos (AA) reali-
zadas en España. 
Método: Se usaron las bases de datos EMBASE y MEDLINE 
y se aplicaron indicadores bibliométricos de productividad y 
dispersión de artículos (leyes de Price y de Bradford, respecti-
vamente). También se calculó el índice de participación (IP) 
de los diferentes países y se buscaron correlaciones entre 
los datos bibliométricos y algunos datos sociales y de salud 
(gasto total per capita en salud y gasto interior bruto en 
investigación y desarrollo). 
Resultados: Se recopilaron 656 artículos originales pu-
blicados entre 1988 y 2011. Nuestros resultados constatan el 
cumplimiento de la ley de Price en la producción científica so-
bre AA, mostrando un crecimiento exponencial (coeficiente de 
correlación r = 0,9693 vs. r = 0,9177 después del ajuste lineal). 
Los fármacos más estudiados fueron la risperidona (181 artí-
culos), la olanzapina (143), la clozapina (94) y la quetiapina 
(74). La división en zonas de Bradford dio lugar a un núcleo 
ocupado por las revistas European Psychiatry y European 
Neuropsychopharmacology (70 artículos). En total se publi-
caron artículos en 194 revistas diferentes, de las cuales 5 
de las 10 primeras tenían un factor de impacto mayor de 4.
Conclusión: Las publicaciones sobre AA en España han 
experimentado un crecimiento exponencial en el período 
estudiado, sin evidencia de que se haya alcanzado un punto 
de saturación. 
Palabras claves: Antipsicóticos atípicos, Bibliometría, Trastorno bipolar, Esquizofrenia, 
España 
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INTRODUCTION
Schizophrenia is a severe mental illness with prevalence 
ranging in Spain between 0.2% and 0.7% of the population1. 
The main therapeutic pillar for schizophrenia during the 
last 60 years have been antipsychotic drugs. The so-called 
“psychopharmacological revolution” in the context of 
treating schizophrenic patients, began in the 1950s with 
the clinical introduction of chlorpromazine2,3 and 
haloperidol4. These first drugs, called first-generation, 
classical or typical, biochemically characterized for 
blocking dopamine receptors, show a great efficacy at 
reducing schizophrenia positive symptoms (hallucinations, 
delusion, etc.). But their main limitation is side effects, 
principally extrapyramidal symptoms (EPS). After the 
reintroduction in the United States of clozapine, an 
antipsychotic drug commercialized in the 1960s, later 
withdrawn due to inducing agranulocytosis5,6, the research 
expectations changed dramatically. Apart from causing 
few EPS, this agent showed efficacy in both positive and 
negative symptoms of schizophrenia as well as in patients 
who are refractory to other antipsychotic treatment7. Also, 
this drug had differential pharmacological characteristics, 
especially at the level of the receptor blockage. Clozapine 
was the third cornerstone on the history of antipsychotic 
pharmacology, and opened the door to the so-called 
“atypical antipsychotics”8 (AADs), with the introduction of 
risperidone in 1993. 
As shown in Table 1, the advances achieved in the field 
of antipsychotic drugs in the past 20 years have been 
incredibly important, with the clinical introduction of 
numerous AADs (risperidone, olanzapine, quetiapine, 
ziprasidone, aripiprazole, etc.). These agents have notably 
improved the quality of life of psychotic patients and have 
contributed decisively to weakening the stigmatization 
that has traditionally accompanied psychiatric attention9. 
With the clinical introduction of the new AADs since 1993 
and, later on, with their licensing for treating bipolar 
disorder since 2003, consumption of these drugs has 
increased enormously. In Spain, AADs accounted for 
already 70% of prescriptions of antipsychotic drugs in 
200610 and between this year and 2011 its use has increased 
by 51%. Clearly, the research on these drugs have also 
advanced considerably, and this has undoubtedly translated 
into a considerable increase in the amount of scientific 
Table 1                Clinical development of atypical antipsychotic drugs 
Company Launch
International Spain
Clozapine Wander Laboratories 1972 a Switzerland 1993
Zotepine Fujisawa 1982 b Japan
Amisulpride Synthelabo 1986 Portugal 2001
Risperidone Johnson & Johnson 1993 UK / Canada 1994
Sertindole Abbott Laboratories / Lundbeck 1996 c UK 1997
Olanzapine Eli Lilly 1996 USA / UK 1996
Quetiapine AstraZeneca 1997 USA / UK 2000
Ziprasidone Pfizer 2001 USA 2002
Perospirone Dainippon Sumitomo Pharma 2001 Japan
Aripiprazole Otsuka / Bristol-Myers Squibb 2002 USA 2004
Paliperidone Janssen Pharmaceutica 2007 USA 2007
Blonanserin Dainippon Sumitomo Pharma 2008 Japan
Asenapine Schering-Plough 2009 USA 2010
Iloperidone Novartis AG 2009 USA
Lurasidone Dainippon Sumitomo Pharma 2011 USA
a Reintroduced in 1990 in USA and UK after being withdrawn from the market in 1975
b Commercialized by Astellas in Germany in 1990
c Marketing authorization was suspended by the European Medicines Agency (EMA) in 1998 and the drug was withdrawn from the market. 
In 2002, based on new data, the EMA suggested that sertindole could be reintroduced for restricted use, and with extensive ECG monitoring 
requirement
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literature on these drugs – as it has been analysed, in the 
specific case of Spain, in this study.
Investments in health care to mentally ill patients in 
Spain are similar to those of other European countries. 
Total health expenditure in Spain accounted for 9.5% of 
gross domestic product (GDP) in 200911. Although the 
actual percentage expended in mental care is not known 
and estimates are unreliable, about 5% of total health 
expenditure can be attributed to mental health12. However, 
the rate of psychiatrists per 100,000 population is lower (8 
vs. 15 in the mean value of the first 27 countries of the 
Organisation for Economic Co-operation and Develop-
ment13). To improve some parameters, the Spanish Ministry 
of Health published in 2006 the document Mental Health 
Strategy in National Health System, one of which 6 
strategic lines is the research in mental health (including 
psychopharmacological research)14. In any case, Spanish 
psychiatric research was already represented in publications 
of greater impact factor of the speciality and was 
comparable in volume to the other countries of our 
surroundings15,16.
The use of bibliometric indicators for studying research 
activity in a specific country in a particular field is based 
on the premise that scientific publication is the essential 
result of such activity17. Bibliometric studies are useful 
tools for assessing the social and scientific relevance of a 
given discipline or field18. Our group has studied, with a 
bibliometric approach, the evolution of scientific literature 
in psychiatry by specific research groups, on different 
psychiatric disorders, on aspects related to the discipline, 
and on specific therapeutic tools in the field of 
psychopharmacology15,19-25. Here, we specifically carried 
out this bibliometric study on AAD publications in Spain.
METHODS
The databases used in this bibliometric study were 
MEDLINE (Index Medicus, U.S. National Library of Medicine, 
Bethesda, Maryland, USA) and Excerpta Medica (Elsevier 
Science Publishers, Amsterdam, Netherlands), which are 
considered the most exhaustive databases in the biomedical 
field, and which both participate in EMBASE Biomedical 
Answer web (Elsevier B.V.).
With remote downloading techniques, we chose papers 
containing, in the AD (author address) section the descriptor 
Spain, and in the TI (title) section, the descriptors atypic* 
(atypical*) antipsychotic*, second-generation antipsychotic*, 
clozapine, risperidone, olanzapine, ziprasidone, quetiapine, 
sertindole, aripiprazole, paliperidone, amisulpride, zotepine, 
asenapine, iloperidone, lurasidone, perospirone and 
blonanserin, published in the period from 1988 to 2011. The 
rest of the descriptors, referring to pharmacological aspects, 
were not restricted to any field of the database. For the 
purposes of this study we considered all original articles, 
brief articles, reviews, editorials, letters-to-the editor, etc., 
and all duplicated papers were omitted. In this regard, the 
database used permits the elimination of items that may be 
duplicated in each of the databases (MEDLINE and EMBASE).
With manual coding after studying the title and/or 
abstracts of the articles, we divided those papers into four 
groups: “experimental pharmacology,” “clinical efficacy,” 
“tolerance and/or safety,” and “not specified group.” 
Among the bibliometric indicators of production we 
applied Price’s law26. This law is the indicator most widely 
used in analysing the productivity of a specific discipline or 
a particular country, to reflect a fundamental aspect of 
scientific production, which is its exponential growth. To 
assess whether the growth of scientific production in AADs 
follows Price’s law of exponential growth, we made a linear 
adjustment of the data obtained, according to the equation 
y = 3.6422x –18.152, and another adjustment to an 
exponential curve, according to the equation y = 
1.071e0.1997x.
As a bibliometric indicator of the dispersion of 
scientific information, we used Bradford’s law. With the 
aim of revealing the distribution of the scientific literature 
in a particular discipline, Bradford proposed a model of 
concentric zones of productivity (Bradford zones) with 
decreasing density of information27. Thus, each zone would 
contain a similar number of papers, but the number of 
journals in which these are published would increase on 
passing from one zone to another. This model permits 
identification of the journals most widely used or with 
greatest weight in a given field of scientific production. 
We used the impact factor (IF) as an indicator of the 
publications’ repercussion [28]. This indicator, developed 
by the Institute for Scientific Information (Philadelphia, 
Pennsylvania, USA), is published annually in the Journal 
Citation Reports (JCR) section of the Science Citation 
Index (SCI). The IF of a journal is calculated on the basis 
of the number of times this journals is cited in the 
source journals of the SCI during the two previous years 
and the total number of articles published by the journal 
in question in these two years. The JCR lists scientific 
journals by specific areas, ascribing to each of them 
their corresponding IF and establishing a ranking of 
“prestige”28. We used the IF data of 2011 published in 
the JCR of 2012.
Another indicator included in the present analysis is 
the national participation index (PI) of Spain for overall 
scientific production (the ratio of the number of papers 
generated by Spain and the total number of papers on this 
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Figure 1               Growth of scientific production on atypical antipsychotic drugs in Spain. A linear adjustment of the data 
was carried out, and a fitting to an exponential curve for AAD papers according to Price’s law26 was found
topic). This PI has also been compared with global PI in 
biomedical and health sciences (as well as for Psychiatry 
and Neurology area in particular). Likewise, the PI has been 
correlated with some health data, such as total per capita 
expenditure on health and gross domestic expenditure on 
research and development (R&D). The PI has also been 
correlated with the corresponding PI for the world’s 15 
most productive countries during the period from 1988 to 
2011. Its health data were obtained from the OECD Health 
Division11, and WHO Department of Health Statistics and 
Informatics29.
RESULTS
After study of the analysed database, during the period 
from 1988 to 2011, we obtained 656 original papers 
(articles, reviews, editorials, letters-to-the-editor, etc.) 
dealing with different aspects related to AADs in Spain. Of 
these, 181 papers correspond to risperidone, 143 to 
olanzapine, 94 to clozapine, 74 to quetiapine, 41 to 
aripiprazole, 37 to ziprasidone, 29 to paliperidone, 21 to 
amisulpride, 2 to sertindole, and 1 to asenapine, blonanserin, 
iloperidone and lurasidone, each. We did not find any 
paper on zotepine and perospirone. Zotepine, perospirone, 
blonanserin, iloperidone and lurasidone are not available 
in Spain.
As illustrated in Figure 1, over the last 25 years there 
has been a marked increase in the number of AAD 
publications generated in Spain. As shown in Figure 1, the 
mathematical adjustment to an exponential curve 
permitted us to obtain a correlation coefficient r = 0.9693, 
indicating 6.05% of variance unexplained by this fitting. In 
contrast, the linear adjustment of the measured values 
provides an r = 0.9177, and therefore a percentage of 
unexplained variance of 15.78%. With these data, we can 
conclude that the database analysed was more in keeping 
Linear adjustment: y = 3.6422x – 18.152 (r2 = 0.8422).
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Figure 2               Number of documents on atypical antipsychotic drugs (1988-2011), use of atypical antipsychotic drugs 
in Spain, and international licensing of different drugs
with an exponential fitting than a linear one, and that the 
postulates of Price’s law were fulfilled. 
The clinical introduction of the new AADs in different 
countries of the world, together with their licensing for 
treating bipolar disorder, is to have contributed 
substantially to the increase in scientific production in the 
AADs field in Spain, as can be seen in Figure 2. This growth 
is closely correlated with the consumption data of AADs in 
Spain. Further, Figure 3 depicts the evolution that has 
occurred in the last two decades of all AAD papers. With 
effects from 2004 and 2008, the growth was mainly due to 
risperidone, and aripiprazole and quetiapine, respectively. 
Figure 4 illustrates the matter even better, by showing that 
cumulative growth in total AAD scientific production in 
Spain was increased in each five-year period compared to 
the previous one with even gradual increment. This growth 
was always higher (in the four consecutive five-year 
periods) compared to the global growth of Spanish science 
in biomedicine and health, and to the specific field of 
Psychiatry and Neurology. 
As regards to the scientific journals in which the AAD 
papers had been published, we applied the Bradford’s 
model. The mean number of articles per Bradford zone was 
65.60, though if we discarded the last zone, whose accuracy 
was obviously lower, the mean would be 72.88. Table 2 
shows the division into Bradford’s areas of the papers in 
this study. The nucleus or first zone would be made up of 
the European Psychiatry and European Neuropsy-
chopharmacology, with 36 and 34 papers, respectively, and 
the second zone Journal of Clinical Psychopharmacology 
(n = 27), Actas Españolas de Psiquiatría (n =27) and 
Journal of Clinical Psychiatry (n = 22). The rest of the 
journals analysed are included in zones 3 to 10. A total of 
194 different journals were used to publish those papers 
analysed. To note, the 10 most used journals accounted for 
34.29% of all papers in this study. 
Table 3 shows these 10 journals most used for the 
diffusion of scientific AAD papers by Spanish authors and 
their corresponding IFs, according to the JCR of 2011, and 
the PI of the journals on total database in the analysed 
period. The journals (Table 3) most extensively used for the 
diffusion of AAD papers have high IFs (7 and 5 of them 
having an IF being greater than 2 and 4, respectively). 
Manually classifying articles, we found that 52.54% of 
them belonged to the “clinical efficacy” group, 18.65% to 
the “tolerance and safety” group, 18.79% to the 
DDD, defined daily dose
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“experimental pharmacology” group, and 10.02% to the 
“not specified” group (mainly, general reviews, pharmaco-
economic analysis and articles of prescribing patterns). 
Clinical studies are mainly devoted to schizophrenia (n = 
139) and bipolar disorder (n = 85), and to a lesser extent, 
to substance abuse disorders (n = 12), depressive disorders 
(n = 8) and Parkinson disease (n = 8).
The general contribution of Spanish science, within 
this thematic area, represents a global PI of 3.59 (sixth in 
the ranking) with respect to world production in period 
analyzed. Table 4 shows that among the countries 
generating most significant AAD research, the USA (whose 
PI is 32.12), is most significant, followed by the United 
Kingdom (PI = 6.73), Germany (PI = 6.32), Canada (PI = 
4.93) and Italy (PI = 4.59). 
If we consider the paper productivity of these 
countries in the field of Psychiatry and Neurology, only 4 
(Spain, India, Sweden, and Brazil) of the 15 largest 
producers in biomedicine and health sciences (in the 
period of 1988-2011) devoted a higher percentage of 
attention to the AAD study (Figure 5). Figure 6 shows the 
correlation between PI and the per capita health 
expenditure and the gross domestic expenditure on R&D 
of each of the countries with the highest scientific 
production in health sciences. 
Table 5 shows the most Spanish productive institutions 
to produce AAD papers in this study. As it can be seen, only 
26.67% of total production was generated in the top ten 
institutions. But the rakings here are solely based on the 
information given in the AD field in the EMBASE Biomedical 
Answer web database, i.e., we identified affiliated 
institutions of the author address of those AAD papers in 
this study.  
Table 2             Distribution of the journals in 
Bradford’s zones







2 3 76 1.5
3 4 67 1.33
4 7 75 1.75
5 8 67 1.14
6 14 72 1.75
7 24 70 1.71
8 43 70 1.79
9 70 70 1.62
10 19 19
Total number of journals = 194
Average number of articles = 65.60
Average number of articles, excluding the last Bradford 
zone = 72.88
Table 3             The 11 journals with highest 
number of publications on atypical 








Journal of Clinical 
Psychopharmacology 
27 4.11 4.098
Actas Españolas de Psiquiatría 27 4.11 0.589





Schizophrenia Research 19 2.89 4.748
Medicina Clínica 14 2.13 1.385
International Journal of 
Neuropsychopharmacology 
13 1.98 4.578
Psiquiatría Biológica 12 1.82 -
Anales de Psiquiatría 12 1.82 -
PI, participation index; IF, impact factor 2011
a Journal Citation Report, 2011 (JCR, 2012)
Figure 3               Evolution of scientific papers on five 
most relevant atypical antipsychotic 
drugs (based on MEDLINE and EMBASE 

























































Mapping the scientific research on atypical antipsychotic drugs in Spain: a bibliometric 
assessment
Francisco López-Muñoz, et al.
355Actas Esp Psiquiatr 2013;41(6):349-60
DISCUSSION
As shown in Figure 1, we found that in this study the 
number of scientific publications had exponentially grown 
over the last 25 years, especially after 2004, and that the 
growth up to the end of this study did not reach saturation 
postulated by Price in his theory of expansion of scientific 
literature26. As indicated in Figure 210, these bibliometric 
data were closely related to the prescription data, which 
have been increased significantly in Spain during the last 
decade30-31. In fact, DDD (defined daily dose / 1,000 
inhabitants / day) of AADs in Spain exceeded the classical 
antipsychotic drugs in 2001, and units sold in 2010 10. 
The increased published AAD papers on were found to 
be coincidental with the approval for marketing by the US 
Food and Drug Administration (FDA) and other international 
regulatory agencies in treating bipolar disorder. Since 
2004, other AADs such as risperidone, quetiapine, 
ziprasidone, aripiprazole, and asenapine, etc. have been 
also approved for treating manic episodes, and olanzapine 
and aripiprazole for relapse prevention in patients with 
bipolar disorder32. Quetiapine is indicated as monotherapy 
for the acute and maintenance treatment of depressive 
episodes of bipolar disorder, and as an add-on treatment 
Table 4             Distribution of documents on atypical antipsychotic drugs in the world’s 15 most productive coun-
tries in biomedicine and health sciences for the period of 1988-2011





1 USA 25.45 35.78 32.12 0.91
2 UK 7.15 9.55 6.73 0.69
3 Japan 6.57 6.89 3.63 0.53
4 Germany 6.05 7.71 6.32 0.83
5 France 4.48 4.99 3.39 0.69
6 Italy 3.77 4.73 4.59 0.98
7 Canada 3.55 4.95 4.93 1.01
8 China 3.46 2.63 2.04 0.79
9 Spain 2.49 2.76 3.59 1.32
10 Australia 2.31 2.93 2.41 0.83
11 Netherlands 2.28 2.86 2.36 0.84
12 India 1.72 1.29 2.33 1.82
13 Sweden 1.56 1.88 2.01 1.08
14 Switzerland 1.48 1.77 1.10 0.68
15 Brazil 1.18 1.22 1.26 1.04
Psy-Neurol, area of focus in Neurology and Psychiatry; AADs, atypical antipsychotic drugs
aThe world’s 15 most productive countries in biomedicine and health sciences for the period of 1988-2011, and b Their productivity in the discipline 
of Psychiatry and Neurology 
Total documents 1988-2011: 16,207,619 
Total documents in Neurology & Psychiatry Area 1988-2011: 1,808,248
Table 5             Contribution of atypical antipsychotic 
drug papers from different 
institutions in Spain 
Institution n
Hospital Clinic de Barcelona 48
Hospital General Universitario Gregorio Marañón (Madrid) 20
Institut d'Investigacions Biomediques August Pi i Sunyer - 
IDIBAPS (Barcelona) 16
Hospital Clínico de Salamanca 15
Universidad de Santiago de Compostela 15
Hospital de la Santa Creu y Sant Pau (Barcelona) 14
Lilly Research Laboratories (Alcobendas, Madrid) 11
Laboratorios Esteve, S.A. (Barcelona) 10
Hospital Universitario Marqués de Valdecilla (Santander) 9
Universidad de Extremadura (Badajoz) 9
Hospital Psiquiátrico Dr. R. Lafora (Madrid) 8
n, number of documents in the study database
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of major depressive disorder when antidepressants alone 
have not been sufficiently effective. Olanzapine-fluoxetine 
combination is indicated for treating treatment-resistant 
major depressive disorder. Aripiprazole was also approved 
in 2007 by the FDA as an add-on to the existing 
antidepressant for treating treatment-resistant major 
depressive disorder32. As indicated in Figure 3, an obvious 
upsurge in the five-year period of 2002-06 was found, 
coinciding with the period of official approval of the new 
AADs and their new indications (bipolar disorder, 
depression, autism, etc.). In the individual analysis of the 
new AADs, risperidone was found to be the agent most 
widely studied in Spain. 
AADs are also commonly used (and studied) in many 
off-label indications, such as substance-induced psychosis, 
agitation symptoms, tics, substance abuse disorders, 
etc.31,33-34. The Spanish Association of Dual Diagnosis 
(Sociedad Española de Patología Dual) was founded six 
years ago by psychiatrists who had worked in the drug 
network and are now integrated into the mental health 
network. These association members have learned to 
prescribe AADs safely and comfortably, with their AAD 
being favorably used in treating substance abuse disorders. 
Those afore-mentioned two factors might have caused the 
increased of publications on AAD in Spain. 
To analyse the quality of papers from Spain, we used 
the indicators of impact and excellence of the publications 
on the topic in question. The fact that prestigious journals 
such as Journal of Clinical Psychiatry (IF = 5.799), 
Schizophrenia Research (IF = 4.748), or International 
Journal of Neuropsychopharmacology (IF = 4.578) 
published articles on AADs from Spain is an important 
factor, indicating the relevance (both clinical and social) 
that this country has acquired in recent years. To note, 
among the 10 publications most widely used in Spain for 
the international divulgation on AAD research, five journals 
are in the ranking of the most relevant in the field of 
Psychiatry (IF in 2011 being greater than 4). 
Psychiatric research in Spain went through a 
remarkable increase in quality and quantity of peer-
reviewed papers during the last two decades, being in 
parallel with other biomedical disciplines15-16,35. Comparing 
the periods of 1994-1995 and 2001-2002, we found that 
the Spanish research production was doubled8. Although 
during the decade of 1980-1989 only 3% (approximately) 
of all scientific publications on Spain were mental health, 
our results showed that during the period of 1988-2011, 
the percentage of papers in the area of Psychiatry and 
Neurology accounted for 12.36% of the total scientific 
production in Spain. As we have shown in recent studies24-25, 
scientific AAD research is one of the fastest growing fields 
within the field of psychiatry. Similarly, some authors with 
bibliometric tools, have reported the research activity in 
the field of schizophrenia being superior to that of other 
fields of psychiatry36. These authors also suggest that the 
attraction of research on schizophrenia may have been 
Figure 4               Cumulative growth by five-year periods 
of scientific production on total 
productivity in biomedicine and health 
sciences, Psychiatry and Neurology 
area, and atypical antipsychotic drugs 
in Spain. Data from each five-year 
period refer to evolution over the 
previous period. The period of reference 
is 1987-91 
Figure 5               Relationship between production 
of scientific literature on atypical 
antipsychotic drugs and total 
production in the field of Psychiatry 
and Neurology in the world’s 15 most 
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positively affected by the clinical perception of the greater 
seriousness of the illness compared to other psychiatric 
pathologies. Moreover, Theander and Wetterberg report 
that the number of references on schizophrenia in MEDLINE 
has followed the general increase of medical publications, 
which accounts for 0.42% compared to the total medical 
literature in the studied period37. 
The two major English-speaking countries, USA and 
UK, head the ranking of paper-producing countries, 
generating totally over a third of total scientific production 
in this field (38.85%). Both countries are home to the 
pharmaceutical companies responsible for the development 
of AADs (olanzapine  – Eli Lilly, USA; risperidone and 
paliperidone – Janssen Pharmaceutica, USA; quetiapine –
AstraZeneca, UK; ziprasidone – Pfizer, USA; and aripiprazole 
– Bristol-Myers Squibb/Otsuka Pharmaceutical Co., USA/
Japan). This fact may help explain why both USA and UK 
have high PI. 
Table 4 shows the data from the 15 most productive 
countries in biomedicine and health sciences and compares 
the data for general productivity in the Psychiatry and 
Neurology discipline with productivity in the specific AAD 
field. To note, Spain, Sweden, India and Brazil sit near the 
top of the ranking for AAD production (see also Figure 5), 
reflecting the special interest of these countries in research 
into these drugs. But Italy and Canada, maintain rates of 
productivity in AAD research that are proportional with 
their global index for psychiatry. Contrariwise, Japan, 
Figure 6               Per capita health expenditure and relationship between production of scientific literature on atypical 
antipsychotic drugs and per capita health expenditure and gross domestic expenditure on R&D, in the 
world’s 15 most productive countries in biomedicine and health sciences
AADs, atypical antipsychotic drugs; R&D, research and development; PI, participation index; PPP, purchasing power parity
Total health expenditure per capita PPP US $ (data from the Organization for Economic and Co-operative Development [OECD] 2009)11
Japan and Australia; Data 2008
China, India and Brazil: Total health expenditure per capita PPP Int $ (data 2008)29
Gross domestic expenditure on R&D (%). Data OECD 2010, except USA and Japan (data 2009), Australia and Switzerland (data 2008), China (data 
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Switzerland, France, or UK has lower relative interest in 
these drugs, within the context of their general production 
in psychiatry. 
Figure 6 shows the correlation of scientific production 
in AADs with the per capita health expenditure of each 
country, offering a similar view of this phenomenon, 
confirming the notion that the higher the spending on 
health, the greater the research production. A country’s 
scientific production in a given field tends to reflect that 
science research and development policy began some years 
before the period analysed, and that they are not the fruit 
of particular economic circumstances21-23. In Spain, during 
the last decade, all new hospitals built (both big general 
hospitals and small regional hospitals) have provided brief 
hospitalization units with residents in psychiatry, which 
has culminated a process of constant medicalisation of 
psychiatry. This has contributed to being able to carry out 
many AAD studies. It is striking, however, to observe the 
low ratios of countries such as Australia, France, Sweden, 
Switzerland or Netherlands. On the contrary, we consider 
that the data for China and India are artifacts due to the 
small per capita health expenditure of these countries (265 
purchasing power parity (PPP) Int $ for China and 122 PPP 
Int $ for India)29.
The correlation analysis between scientific AAD 
production and the gross domestic expenditure on R&D 
located to Sweden and Switzerland in the last two 
positions. Spain ranks third in the ranking, behind UK and 
Italy. In this sense, the greatest number of research projects 
obtaining funding from the “Fondo de Investigación 
Sanitaria,” a main public funder in Spain, have been in the 
thematic area of Neurological and Mental Diseases 
(15.52%)38. Totally 44 projects were funded in 2001 (€ 2.08 
million), 337 in 2005 (€ 12.25 million), and 118 in 2010 (€ 
12.02 million)14,38. Moreover, the research at the Carlos III 
Research Institute were predominantly biologically driven 
in strategies. As part of this institution were created in 
2006 Networks and Cibers, such as CIBERSAM, which 
groups most of the research teams of Spain, where 
schizophrenia and bipolar disorder take up most of the 
resources, both public and private. Within these disorders, 
AADs have played a leading role. This correlates closely 
with results obtained in this study.
LIMITATIONS AND STRENGTHS OF THE STUDY
The readers are warned against over-interpreting the 
study findings because this study has three major 
limitations which are inherent to its bibliometric nature39. 
First, not all the AAD papers from Spain were included. This 
bibliometric study includes papers from EMBASE Biomedical 
Answer web. The criteria set by the databases themselves 
determine the subsequent development of the studied 
materials17,40. Excluded are those papers on AADs if authors 
do not put the AAD descriptors in the titles or key words of 
the papers, national or local journals that are not included 
in MEDLINE and Excerpta Medica, and those contributions 
at scientific conferences and meetings19. Second, we 
included only those papers with Spanish corresponding 
authors in this study. And third, the use of indicator impact 
factor to determine the merit or quality of scientific 
contributions is still debatable. The citation count may 
mean that the given topic is the study is “not yet mature” 
and is “in need of more studies.” But it may not mean the 
work is more important than those papers which do not 
get many citations. Differing in those in the Europe and 
Asia, American universities do not use impact factor as 
much to measure the production of a faculty member.
In spite of the above-listed study limitations, 
bibliometric studies are useful in assessing the social and 
scientific relevance of a given discipline or field18. Those 
studies constitute an effective complement for the 
opinions and judgments of experts in each field, giving 
useful and objective tools to evaluate the results of 
scientific activity, offering a more realistic view of the 
picture and an indication of trends, as well as predicting 
how it might evolve41.
CONCLUSION 
Keeping in mind of the above-listed limitations and 
strengths, we have been able to offer a picture of the 
representativeness and evolution of international research 
on AADs in Spain, observing the parameters of quality and 
dissemination most commonly employed at an international 
level. This study results confirm that the research in AADs 
carried out in Spain have a good level currently and has 
made a positive evolution in the last two decades, similar 
to what happened in other fields of biomedical research16. 
AADs as a group of pharmaceutic class started to 
become number 1 in the market sale (US$ 14.6 billion per 
year) in 2008 in the USA32. Any new AAD, as a commercial 
commodity, can easily become an instant “mega-drug” (by 
the definition of having the annual sale of US$ 500 million) 
if it can occupy only 4% of market share in the USA32. Thus, 
research in this field will definitely continue to grow in the 
coming years. To note, the ideal antipsychotic drug has not 
yet been found9, and that the need of treating many 
treatment-resistant patients is waiting to be met41. 
Besides, AADs have, and will continue to have, an ever-
expanding range of clinical indications, both within the 
psychiatric ambit and outside it, to judge from the 
promising results obtained for the different pathologies 
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with which they have been studied34; in consequence, 
scientific production in relation to these drugs will certainly 
continue to be abundant.
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